Downregulation of hypoxia-related responses by novel antitumor histone deacetylase inhibitors in MDAMB231 breast cancer cells

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 4, 2012, Pages 407-413

  Naldini, Antonella ^a   Filippi, Irene ^a   Cini, Elena ^a   Rodriquez, Manuela ^b   Carraro, Fabio ^a   Taddei, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Angiogenesis; Anticancer drugs; Breast cancer; Carbonic anhydrase; Cell proliferation; Epigenetic regulation; Gene expression; Glucose transporter; Histone deacetylase inhibitors; Hypoxia; Hypoxia inducible factor (HIF) 1alpha; Metabolism; Transcription factors; Tumor microenvironment; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; FR 235222; GLUCOSE TRANSPORTER 1; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BNIP3; SYNAPSIN II; TETRAPEPTIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VASCULOTROPIN; VORINOSTAT;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING;

EID: 84860511076     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800228706     Document Type: Article

References (48)

1. Pouyssegur, J.; Dayan, F.; Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumor regression. Nature, 2006, 44 (7092), 437-443.
2. Poellinger, L.; Johnson, R. S. HIF-1 and hypoxic response: the plot thickens. Curr. Opin. Genet. Dev., 2004, 14(1), 81-85.
3. Weidemann, A.; Johnson, R. S. Biology of HIF-1alpha. Cell Death. Differ., 2008, 15(4), 621-627.
4. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003, 3(10), 721-732.
5. Semenza, G. L.; Roth, P. H.; Fang, H.-M.; Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem., 1994, 269(38), 23757-23763.
6. Pugh, C. W.; Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med., 2003, 9(6), 677-684.
7. Park, S. K.; Dadak, A. M.; Haase, V. H.; Fontana, L.; Giaccia, A. J.; Johnson, R. S. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. Mol. Cell Biol., 2003, 23(14), 4959-4971.
8. Scortegagna, M.; Ding, K.; Oktay, Y.; Gaur, A.; Thurmond, F.; Yan, L. J.; Marck, B. T.; Matsumoto, A. M.; Shelton, J. M.; Richardson, J. A.; Bennett, M. J.; Garcia, J. A. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/-mice. Nat. Genet., 2003, 3 (4), 331-340.
9. Brahimi-Horn, C.; Mazure, N.; Pouyssegur, J. Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal., 2005, 17(1), 1-9.
10. Kong, X.; Lin, Z.; Liang, D.; Fath, D.; Sang, N.; Caro, J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell Biol., 2006, 26(6), 2019-2028.
11. Qian, D. Z.; Kachhap, S. K.; Collis, S. J.; Verheul, H. M.; Carducci, M. A.; Atadja, P.; Pili, R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxiainducible factor 1 alpha. Cancer Res., 2006, 66(17), 8814-8821.
12. Kato, H.; Tamamizu-Kato, S.; Shibasaki, F. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J. Biol. Chem., 2004, 279(40), 41966-41974.
13. Kim, M. S.; Kwon, H. J.; Lee, Y. M.; Baek, J. H.; Jang, J. E.; Lee, S. W.; Moon, E. J.; Kim, H. S.; Lee, S. K.; Chung, H. Y.; Kim, C. W.; Kim, K. W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med., 2001, 7(4), 437-443.
14. Mie, L. Y.; Kim, S. H.; Kim, H. S.; Jin, S. M.; Nakajima, H.; Jeong, K. H.; Kim, K. W. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun., 2003, 300(1), 241-246.
15. Richon, V. M.; Sandhoff, T. W.; Rifkind, R. A.; Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U. S. A, 2000, 97(18), 10014-10019.
16. Abramova, M. V.; Pospelova, T. V.; Nikulenkov, F. P.; Hollander, C. M.; Fornace, A. J., Jr.; Pospelov, V. A. G1/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A + Rastransformed cells is mediated through down-regulation of E2F activity and stabilization of beta-catenin. J. Biol. Chem., 2006, 281(30), 21040-21051.
17. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer, 2006, 6(1), 38-51.
18. Chen, S.; Sang, N. Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J. Biomed. Biotechnol., 2011, 2011, 197946.
19. Semenza, G. L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today, 2007, 12(19-20), 853-859.
20. Ellis, L.; Hammers, H.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett., 2009, 280 (2), 145-153.
21. Gomez-Paloma, L.; Bruno, I.; Cini, E.; Khochbin, S.; Rodriquez, M.; Taddei, M.; Terracciano, S.; Sadoul, K. Design and synthesis of cyclopeptide analogs of the potent histone deacetylase inhibitor FR235222. ChemMedChem., 2007, 2(10), 1511-1519.
22. Petrella, A.; D'Acunto, C. W.; Rodriquez, M.; Festa, M.; Tosco, A.; Bruno, I.; Terracciano, S.; Taddei, M.; Paloma, L. G.; Parente, L. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur. J. Cancer, 2008, 44(5), 740-749.
23. Sasamura, S.; Sakamoto, K.; Takagaki, S.; Yamada, T.; Takase, S.; Mori, H.; Fujii, T.; Hino, M.; Hashimoto, M. AS1387392, a novel immunosuppressive cyclic tetrapeptide compound with inhibitory activity against mammalian histone deacetylase. J. Antibiot. (Tokyo), 2010, 63(11), 633-636.
24. Vaupel, P.; Schlenger, K.; Knoop, C.; Höckel, M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res., 1991, 51, 3316-3322.
25. Rodriquez, M.; Bruno, I.; Cini, E.; Marchetti, M.; Taddei, M.; Gomez-Paloma, L. Synthesis of 2-amino-8-oxodecanoic acids (Aodas) present in natural hystone deacetylase inhibitors. J. Org. Chem., 2006, 71(1), 103-107.
26. Naldini, A.; Carraro, F.; Silvestri, S.; Bocci, V. Hypoxia affects cytokine production and proliferative responses by human peripheral mononuclear cells. J. Cell. Physiol., 1997, 173(3), 335-342.
27. Naldini, A.; Filippi, I.; Ardinghi, C.; Silini, A.; Giavazzi, R.; Carraro, F. Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. Eur. J. Cancer, 2009, 45(3), 454-460.
28. Boraldi, F.; Annovi, G.; Carraro, F.; Naldini, A.; Tiozzo, R.; Sommer, P.; Quaglino, D. Hypoxia influences the cellular crosstalk of human dermal fibroblasts. A proteomic approach. Biochim. Biophys. Acta, 2007, 1774(11), 1402-1413.
29. Naldini, A.; Morena, E.; Pucci, A.; Pellegrini, M.; Baldari, C. T.; Pelicci, P. G.; Presta, M.; Ribatti, D.; Carraro, F. The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells. J. Leukoc. Biol., 2010, 87(3), 365-369.
30. Vandesompele, J.; De, P. K.; Pattyn, F.; Poppe, B.; Van, R. N.; De, P. A.; Speleman, F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol., 2002, 3(7), 1-12.
31. Manetti, F.; Brullo, C.; Magnani, M.; Mosci, F.; Chelli, B.; Crespan, E.; Schenone, S.; Naldini, A.; Bruno, O.; Trincavelli, M. L.; Maga, G.; Carraro, F.; Martini, C.; Bondavalli, F.; Botta, M. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J. Med. Chem., 2008, 51(5), 1252-1259.
32. Yu, J. L.; Coomber, B. L.; Kerbel, R. S. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation, 2002, 70(9-10), 599-609.
33. Kallinowski, F.; Schlenger, K. H.; Runkel, S.; Kloes, M.; Stohrer, M.; Okunieff, P.; Vaupel, P. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res., 1989, 49, 3759-3764.
34. Höckel, M.; Schlenger, K.; Knoop, C.; Vaupel, P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res., 1991, 51, 6098-6102.
35. Blasina, A.; de Weyer, I. V.; Laus, M. C.; Luyten, W. H.; Parker, A. E.; McGowan, C. H. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr. Biol., 1999, 9(1), 1-10.
36. Jeong, J. W.; Bae, M. K.; Ahn, M. Y.; Kim, S. H.; Sohn, T. K.; Bae, M. H.; Yoo, M. A.; Song, E. J.; Lee, K. J.; Kim, K. W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell, 2002, 111(5), 709-720.
37. Semenza, G. L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol., 1999, 15, 551-578.
38. Mellor, H. R.; Harris, A. L. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Rev., 2007, 26(3-4), 553-566.
39. Bellot, G.; Garcia-Medina, R.; Gounon, P.; Chiche, J.; Roux, D.; Pouyssegur, J.; Mazure, N. M. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol. Cell Biol., 2009, 29(10), 2570-2581.
40. Goonewardene, T. I.; Sowter, H. M.; Harris, A. L. Hypoxiainduced pathways in breast cancer. Microsc. Res. Tech., 2002, 59(1), 41-48.
41. Robey, I. F.; Stephen, R. M.; Brown, K. S.; Baggett, B. K.; Gatenby, R. A.; Gillies, R. J. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia., 2008, 10(8), 745-756.
42. Gillies, R. J.; Robey, I.; Gatenby, R. A. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med., 2008, 49 Suppl 2, 24S-42S.
43. Chiche, J.; Ilc, K.; Laferriere, J.; Trottier, E.; Dayan, F.; Mazure, N. M.; Brahimi-Horn, M. C.; Pouyssegur, J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res., 2009, 69(1), 358-368.
44. Brizel, D. M.; Schroeder, T.; Scher, R. L.; Walenta, S.; Clough, R. W.; Dewhirst, M. W.; Mueller-Klieser, W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 2001, 51(2), 349-353.
45. Kroemer, G.; Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell, 2008, 13(6), 472-482.
46. Denko, N. C.; Giaccia, A. J. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res., 2001, 61(3), 795-798.
47. Brown, J. M.; Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 1998, 58, 1408-1416.
48. Zou, W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer, 2005, 5(4), 263-274.